Stockscreener 앱 받기
122.68
1.85%
-2.31
시장 영업 전:
122.68
전일 마감가:
$124.99
열려 있는:
$124.98
하루 거래량:
1.40M
Relative Volume:
0.96
시가총액:
$17.98B
수익:
$9.82B
순이익/손실:
$1.48B
주가수익비율:
12.11
EPS:
10.13
순현금흐름:
$2.30B
1주 성능:
-7.84%
1개월 성능:
-3.43%
6개월 성능:
-12.98%
1년 성능:
-45.81%
1일 변동 폭
$121.05
$125.42
1주일 범위
$121.05
$133.36
52주 변동 폭
$110.03
$236.48
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
BIIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
122.68 | 19.50B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Is Biogen Inc. a good long term investmentExplosive wealth accumulation - jammulinksnews.com
Biogen investing $2B to expand operations in RTP - ABC11
Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth - AInvest
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - yahoo.co
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - Biogen
Biogen Breakthrough: 48-Month LEQEMBI Results Plus Game-Changing Subcutaneous Alzheimer's Treatment Option - Stock Titan
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - Yahoo.co
Biogen to invest $2 billion in RTP facility - CBS 17
Biogen Inc. Invests $2B In North Carolina Expansion - Business Facilities
Biogen Inc. Announces $2 Billion Expansion in North Carolina's Research Triangle Park Amid U.S. Manufacturing Push - Hoodline
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance
Biogen, one of the largest employers in RTP, plans $2B investment in the Triangle - Axios
Biogen Bets Big On $2 Billion Expansion To Boost US Drug ManufacturingBiogen (NASDAQ:BIIB) - Benzinga
Biogen invests $2B in U.S. manufacturing — but not in Massachusetts - The Business Journals
Biogen to make $2 billion investment in Research Triangle Park - CBS 17
Biogen to invest $2 billion in RTP, open new factory in 2025 - WRAL.com
Biogen’s Pediatric RRMS Study Completion: Market Implications and Insights - TipRanks
Biogen (NASDAQ:BIIB) Now Covered by Analysts at Truist Financial - MarketBeat
Biogen to invest further $2 billion in North Carolina facilities - The Pharma Letter
Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm - Reuters
Drugmaker Biogen to invest $2 billion more in North Carolina - 104.1 WIKY
Truist downgrades Biogen, citing growth challenges, limited pipeline upside - TradingView
Biogen Announces Additional Investment In North Carolina's RTP - Nasdaq
Biogen (BIIB) Increases Investment in North Carolina Manufacturi - GuruFocus
Biogen to invest $2 billion more in North Carolina By Reuters - Investing.com
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary | BIIB Stock News - GuruFocus
Biogen to invest $2 billion in North Carolina manufacturing expansion By Investing.com - Investing.com India
Biogen Announces $2 Billion Investment to Expand Manufacturing in North Carolina's Research Triangle Park - Quiver Quantitative
Biogen to invest $2 billion more in North Carolina - Reuters
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary - The Manila Times
Biogen Commits $2B for Manufacturing Expansion in Research Triangle Park | BIIB Stock News - Stock Titan
Twin Capital Management Inc. Has $1.58 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Central Nervous System (CNS) Biomarkers Market is expected - openPR.com
Q3 Earnings Estimate for Biogen Issued By William Blair - MarketBeat
Biogen Inc. Stock Analysis and ForecastUnprecedented profits - PrintWeekIndia
Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
What analysts say about Biogen Inc. stockRapid wealth accumulation - Jammu Links News
Brokerages Set Biogen Inc. (NASDAQ:BIIB) Price Target at $188.48 - MarketBeat
New York State Common Retirement Fund Purchases 20,130 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Cwm LLC - MarketBeat
Alps Advisors Inc. Purchases New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
What drives Biogen Inc. stock priceExceptional profit velocity - Autocar Professional
Wedbush Issues Pessimistic Forecast for Biogen Earnings - MarketBeat
Cerity Partners LLC Has $5.52 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Rachid Izzar Sells 2,223 Shares of Biogen Inc. (NASDAQ:BIIB) Stock - MarketBeat
Insider Selling Spree: Fastly, Biogen, Kroger, Bloom, and Pure Investors Unload Shares - AInvest
AustralianSuper Pty Ltd Makes New $54.42 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know - TradingView
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
0.06%
자본화:
|
볼륨(24시간):